Back to all studies
Active Not RecruitingNCT05841030

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

This active not recruiting study focuses on depression and currently lists sites or participation links in Argentina, Brazil, Canada, France, Germany, Italy, South Korea, Spain, Sweden, United Kingdom, United States.

DepressionOtherFrom 18 Years to 74 Years
In plain English

Key information made simple

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand what a therapy or guided support program could change in day-to-day care and decision-making. For people living with Depression, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including University of Alabama at Birmingham in Birmingham, University of Alabama at Birmingham in Homewood, and ATP Clinical Research in California City. Participation appears to center on questionnaires, assessments, or follow-up information rather than a study treatment. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include safety concerns that need urgent care first and other factors that could make participation unsuitable. The official record does not list a trial phase, which usually means the study is focused on observation rather than testing a staged treatment.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Interested?

Check my eligibility

Study reference: NCT05841030. Your email is the only field you need to provide here.
In practice

For you

Taking part may help improve understanding of your condition.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Argentina.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) | HopeStage Research